Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL16339180 | 0.82 | ENPP2 (0.45) | CCR5ENPP2SIGMAR1CASP1HDAC1 | |
| SCHEMBL1773629 | 0.80 | SIGMAR1 (0.43) | CCR5ENPP2SIGMAR1MMECTSL | |
| SCHEMBL1761244 | 0.79 | ENPP2 (0.48) | ENPP2SIGMAR1HDAC1HDAC6ALDH1A1 | |
| SCHEMBL392447 | 0.75 | ATM (0.45) | CASP1CTSLCTSBCTSSCTSK | |
| Sulfurous Acid SCHEMBL1774500 | 0.75 | ENPP2 (0.45) | CCR5ENPP2SIGMAR1CTSLCTSB | |
| SCHEMBL1630384 | 0.75 | ATM (0.45) | CASP1CTSLCTSBCTSSCTSK | |
| SCHEMBL392448 | 0.75 | ATM (0.45) | CASP1CTSLCTSBCTSSCTSK | |
| SCHEMBL387235 | 0.74 | ATM (0.44) | CASP1CTSLCTSBCTSSCTSK | |
| Bicarbonate SCHEMBL7273519 | 0.73 | SIGMAR1 (0.53) | CCR5ENPP2SIGMAR1CTSLCTSB | |
| SCHEMBL19525612 | 0.73 | SIGMAR1 (0.55) | CCR5ENPP2SIGMAR1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9949963-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160287572-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160287572-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9290491-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290491-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150073014-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20150073014-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8816091-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-8816091-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20140080856-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080856-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8536335-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536335-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130072515-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8247555-B2 | Crystalline forms of an 8-azabicyclo[3.2.1]octane compound | THERAVANCE, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110184008-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | THERAVANCE, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-7943772-B2 | Crystalline forms of an 8-azabicyclo(3.2.1)octane compound | THERAVANCE, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184008-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | CCR5 218/4885ENPP2 775/4885SIGMAR1 2/4885 |
| US-20160287572-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | CCR5 218/4885ENPP2 775/4885SIGMAR1 2/4885 |
| US-20130072515-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | CCR5 238/4885ENPP2 836/4885SIGMAR1 2/4885 |
| US-20180200246-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | CCR5 218/4885ENPP2 775/4885SIGMAR1 2/4885 |
| US-20140080856-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | CCR5 218/4885ENPP2 775/4885SIGMAR1 2/4885 |
| US-20080207676-A1 | Crystalline forms of an 8-Azabicyclo(3.2.1)octane compound | OPRM1, SIGMAR1, OPRD1 | CCR5 201/4885ENPP2 749/4885SIGMAR1 2/4885 |
| US-20150073014-A1 | CRYSTALLINE FORMS OF AN 8-AZABICYCLO[3.2.1]OCTANE COMPOUND | OPRM1, SIGMAR1, OPRD1 | CCR5 218/4885ENPP2 775/4885SIGMAR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.